| Lubiprostone: evaluation of the newest medication for the treatment of adult women with constipation-predominant irritable bowel syndrome. | |
| | |
MedLine Citation:
|
PMID: 21151683 Owner: NLM Status: In-Data-Review |
Abstract/OtherAbstract:
|
Irritable bowel syndrome (IBS) is a chronic disorder that affects primarily female patients and is thought also to afflict approximately 7%-10% of the population of the Western World. Although bowel habits may change over the course of years, patients with IBS are characterized according to their predominant bowel habit, constipation (IBS-C), diarrhea (IBS-D), or mixed type (IBS-M), and treatments are focused toward the predominant symptom. Current treatments for IBS-C have included fiber, antispasmodics, osmotic and stimulant laxatives, and the now severely limited 5-HT(4) agonist tegaserod. No one agent has been universally successful in the treatment of this bothersome syndrome and the search for new agents continues. Lubiprostone (Amitiza(®)), a novel compound, is a member of a new class of agents called prostones and was approved for the treatment of chronic idiopathic constipation in 2006 at a dose of 24 μg twice daily and then in 2008 for the treatment of IBS-C in women only at a dose of 8 μg twice daily. Its purported mechanism is as a type 2 chloride channel activator, but recent evidence suggests that it may also work at the cystic fibrosis transport receptor. This article will compare the newly proposed mechanism of action of this compound to the purported mechanism and review the structure, pharmacology, safety, efficacy, and tolerability of this new therapeutic option. Clinical trial data leading to the approval of this agent for the treatment of IBS-C and the gender-based understanding of IBS, as well as this agent's place among existing and emerging therapies, will be examined. |
| | |
Authors:
|
Tisha N Lunsford; Lucinda A Harris |
Related Documents
:
|
1070343 - Horner'sy syndrome and its significance in the management of head and neck trauma. 19485573 - Delay eyeblink classical conditioning is impaired in fragile x syndrome. 8651253 - Renal tubular acidosis and deafness: report of a large family. |
Publication Detail:
|
Type: Journal Article Date: 2010-10-27 |
Journal Detail:
|
Title: International journal of women's health Volume: 2 ISSN: 1179-1411 ISO Abbreviation: Int J Womens Health Publication Date: 2010 |
Date Detail:
|
Created Date: 2010-12-14 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 101531698 Medline TA: Int J Womens Health Country: New Zealand |
Other Details:
|
Languages: eng Pagination: 361-74 Citation Subset: - |
Affiliation:
|
Department of Gastroenterology and Hepatology, Mayo Clinic - School of Medicine, Scottsdale, Arizona, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Zoledronic acid infusion for prevention and treatment of osteoporosis.
Next Document: Characteristics measured by the Eating Disorder Inventory for children at risk and protective factor...